6-溴-咪唑并[1,2-a]吡啶-2-乙醇 | 864867-36-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 6-溴-咪唑并[1,2-a]吡啶-2-乙醇
• 英文名称: 2-(6-bromoimidazo[1,2-a]pyridin-2-yl)ethanol
• 英文别名: 2-(6-bromoimidazo[1,2-a]pyridine-2-yl)ethanol
• CAS: 864867-36-7
• 化学式: C₉H₉BrN₂O
• 分子量: 241.087
• InChiKey: GOLMJRBLGNEGAB-UHFFFAOYSA-N

物化性质

• 密度：
  1.65±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-溴-咪唑并[1,2-a]吡啶-2-乙醇 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 生成 6-bromo-2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]imidazo[1,2-a]pyridine
  参考文献：
  名称：

  [EN] IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF
  [FR] DÉRIVÉS D'IMIDAZOLE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明涉及新型咪唑化合物，包括该咪唑化合物的药物组成物，并使用这些化合物来治疗或预防过敏、过敏引起的气道反应、充血、心血管疾病、炎症性疾病、胃肠道疾病、神经系统疾病、代谢性疾病、肥胖症或与肥胖相关的疾病、糖尿病、糖尿病并发症、糖耐量受损或空腹血糖受损。本发明的一种示例化合物如下所示：

  公开号：

  WO2011060235A1
• 作为产物：
  描述：

  6-溴咪唑并[1,2-A]吡啶-2-乙酸乙酯 在 三乙基硼氢化锂 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以15%的产率得到6-溴-咪唑并[1,2-a]吡啶-2-乙醇
  参考文献：
  名称：

  [EN] FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
  [FR] DÉRIVÉS D'IMIDAZOLE TRICYCLIQUES FUSIONNÉS EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU TNF

  摘要：

  一系列替代的融合三环咪唑衍生物，特别是二氢-1H-吡喃[4',3':4,5]咪唑[1,2-a]吡啶，1,2,3,4-四氢咪唑[1,2-a:5,4-c']二吡啶，二氢-1H-吡喃[3',4':4,5]咪唑[1,2-a]吡啶和四氢-6H-环庚七[4,5]咪唑[1,2-a]吡啶，及其类似物，作为人类TNFα活性的有效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经学和神经退行性疾病；疼痛和伤害感知性疾病；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。

  公开号：

  WO2015086527A1

文献信息

• Dairyl-substituted five-membered heterocycle derivative
  申请人：Hirata Yukari

  公开号：US20070173507A1

  公开（公告）日：2007-07-26

  The present invention provides the compounds represented by formula (I): (I) or pharmaceutical salts thereof, wherein: X 1 represents oxygen atoms and the like, X 2 represents nitrogen atoms and the like, X 3 represents nitrogen atoms and the like, X 4 represents nitrogen atoms and the like, R 1 represents formula (II-1): wherein X 5 represents sulfur atoms and the like, A 1 represents carbon atoms and the like, A 2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being usefull for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

  本发明提供了由公式（I）所表示的化合物：（I）或其药物盐，其中：X1代表氧原子等，X2代表氮原子等，X3代表氮原子等，X4代表氮原子等，R1代表公式（II-1）：其中X5代表硫原子等，A1代表碳原子等，A2代表氮原子等，A环代表苯基等，具有mGluR1抑制作用，适用于预防或治疗惊厥、急性疼痛、炎症性疼痛、慢性疼痛、脑部疾病如脑梗死或短暂性脑缺血发作、精神疾病如精神分裂症、焦虑、药物依赖、帕金森病或胃肠道疾病。
• DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE
  申请人：Hirata Yukari

  公开号：US20110160208A1

  公开（公告）日：2011-06-30

  The present invention provides the compounds represented by formula (I): or pharmaceutical salts thereof, wherein: X 1 represents oxygen atoms and the like, X 2 represents nitrogen atoms and the like, X 3 represents nitrogen atoms and the like, X 4 represents nitrogen atoms and the like, R 1 represents formula (II-1): wherein X 5 represents sulfur atoms and the like, A 1 represents carbon atoms and the like, A 2 represents nitrogen atoms and the like and A ring represents phenyl group and the like, having mGluR1 inhibiting effect, and being useful for preventing or treating convulsion, acute pain, inflammatory pain, chronic pain, brain disorder such as cerebral infarction or transient ischemick attack, psychotic disorder such as schizophrenia, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorder.

  本发明提供了以下式子(I)所代表的化合物或其药物盐，其中：X1代表氧原子等，X2代表氮原子等，X3代表氮原子等，X4代表氮原子等，R1代表式子(II-1)：其中X5代表硫原子等，A1代表碳原子等，A2代表氮原子等，环A代表苯基等，具有mGluR1抑制作用，并且对于预防或治疗惊厥、急性疼痛、炎症性疼痛、慢性疼痛、脑部疾病如脑梗死或短暂性缺血性发作、精神障碍如精神分裂症、焦虑、药物依赖、帕金森病或胃肠疾病有用。
• FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
  申请人：UCB Biopharma SPRL

  公开号：EP3080114A1

  公开（公告）日：2016-10-19
• IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Rao Ashwin U.

  公开号：US20120225885A1

  公开（公告）日：2012-09-06

  The present invention relates to novel imidazole compounds, pharmaceutical compositions comprising the imidazole compounds and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below:
• Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity
  申请人：UCB BIOPHARMA SPRL

  公开号：US20160304530A1

  公开（公告）日：2016-10-20

  A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4′,3′:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c′]dipyridine, dihydro-1H-pyrano[3′,4′:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogues thereof, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.